Literature DB >> 27347209

Incidental and non-incidental thyroid microcarcinoma.

Krzysztof Kaliszewski1, Beata Wojtczak1, Marta Strutyńska-Karpińska2, Tadeusz Łukieńczuk1, Zdzisław Forkasiewicz1, Paweł Domosławski1.   

Abstract

There is no clear therapeutic approach for thyroid microcarcinoma (TMC). This may be as a consequence of recent observations that have reported biologically different types of TMC, which should be treated differently. The objective of the present study was to compare incidental TMC (ITMC) and non-incidental TMC (NITMC) in order to assess the differences in the incidence, diagnostic results, clinicopathological characteristics and surgical treatment. The study consisted of a retrospective chart review of 3,218 patients consecutively admitted and surgically treated in a single institution due to thyroid pathology. A total of 246 (7.64%) patients presented with a thyroid malignancy, and 97 (39.43%) of these individuals were diagnosed with TMC; 37 (38.14%) patients exhibited ITMC and 60 (61.86%) exhibited NITMC. All 37 (100.00%) patients with ITMC exhibited a papillary type of cancer. In the NITMC group, 1 (1.67%) patient presented with follicular microcarcinoma, 1 (1.67%) individual with papillary- and follicular-type microcarcinoma, 1 (1.67%) individual with medullary microcarcinoma, and the remaining 57 (95.00%) patients presented with papillary microcarcinoma. The number of younger patients (<45 years old) was higher in the NITMC group, but this difference was not significant (P=0.205). In all patients with ITMC, ultrasound-guided fine-needle aspiration biopsy did not reveal malignant processes. In the NITMC group, the number of larger tumors (>5 mm) was significantly higher compared with that in the ITMC group (P<0.001). ITMC was significantly associated with multinodular goiter (MNG) (P<0.001). Amongst the NITMC group, 18.33% of patients presented with cervical lymph node involvement (P<0.001). Overall, the incidence of TMC is high, and consists of ITMC and NITMC, although the prevalence of NITMC is higher than that of ITMC. The majority of ITMCs and NITMCs are composed of a papillary type of cancer. The majority of ITMCs have dimensions ≤5 mm in diameter and are significantly associated with MNG. In comparison with ITMC, NITMC more often presents with aggressive features such as cervical lymph node metastases, so the surgical approach to this tumor should be more radical.

Entities:  

Keywords:  cancer; incidental; microcarcinoma; thyroid

Year:  2016        PMID: 27347209      PMCID: PMC4907287          DOI: 10.3892/ol.2016.4640

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  39 in total

1.  American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations.

Authors:  H Gharib; E Papini; R Paschke; D S Duick; R Valcavi; L Hegedüs; P Vitti
Journal:  J Endocrinol Invest       Date:  2010       Impact factor: 4.256

2.  High risk for microcarcinoma in thyroid benign diseases. Incidence in a one year period of total thyroidectomies.

Authors:  M Carlini; C Giovannini; F Castaldi; E Mercadante; R Dell'Avanzato; S Zazza; A Nania; G Santeusanio; M Passeri; P Di Perna
Journal:  J Exp Clin Cancer Res       Date:  2005-06

3.  Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-11       Impact factor: 3.352

4.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

5.  [Diagnosis and treatment of thyroid microcarcinoma].

Authors:  Jiajia Feng; Jiadong Wang
Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi       Date:  2014-12

6.  Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough?

Authors:  Markus Dietlein; Walter A Luyken; Harald Schicha; Antonio Larena-Avellaneda
Journal:  Nucl Med Commun       Date:  2005-01       Impact factor: 1.690

7.  Should central lymph node dissection be considered for all papillary thyroid microcarcinoma?

Authors:  Young Woo Chang; Hwan Soo Kim; Hoon Yub Kim; Jae Bok Lee; Jeoung Won Bae; Gil Soo Son
Journal:  Asian J Surg       Date:  2015-04-22       Impact factor: 2.767

8.  Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area.

Authors:  Celestino P Lombardi; Rocco Bellantone; Carmela De Crea; Nunzia C Paladino; Guido Fadda; Massimo Salvatori; Marco Raffaelli
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

9.  Geographic pathology of occult thyroid carcinomas.

Authors:  F H Fukunaga; R Yatani
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

10.  Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients.

Authors:  Elio Roti; Roberta Rossi; Giorgio Trasforini; Fiorenza Bertelli; Maria Rosaria Ambrosio; Luciano Busutti; Elizabeth N Pearce; Lewis E Braverman; Ettore C Degli Uberti
Journal:  J Clin Endocrinol Metab       Date:  2006-02-14       Impact factor: 5.958

View more
  5 in total

1.  Analysis of Malignant Thyroid Neoplasms with a Striking Rise of Papillary Microcarcinoma in an Endemic Goiter Region.

Authors:  Alka Mary Mathai; K Preetha; S Valsala Devi; Sam Vicliph; Raja Pradeep; Aqib Shaick
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-07-20

2.  Diagnostic Accuracy of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Detecting Occult Papillary Thyroid Microcarcinomas in Benign Multinodular Goitres.

Authors:  Dimitrios K Manatakis; Sophia Tseleni-Balafouta; Lazaros Tzelves; Dimitrios Balalis; Adelais Tzortzopoulou; Dimitrios P Korkolis; George H Sakorafas; Emmanouil Gontikakis; Georgios Plataniotis
Journal:  J Thyroid Res       Date:  2018-04-23

3.  Comparison of the prevalence of incidental and non-incidental papillary thyroid microcarcinoma during 2008-2016: a single-center experience.

Authors:  Krzysztof Kaliszewski; Agnieszka Zubkiewicz-Kucharska; Paweł Kiełb; Jerzy Maksymowicz; Aleksander Krawczyk; Otto Krawiec
Journal:  World J Surg Oncol       Date:  2018-10-10       Impact factor: 2.754

4.  Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population.

Authors:  Donnie Funch; Kathleen Mortimer; Najat J Ziyadeh; John D Seeger; Li Zhou; Eva Ng; Douglas Ross; Atheline Major-Pedersen; Heidrun Bosch-Traberg; Helge Gydesen; David D Dore
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-10       Impact factor: 3.168

5.  The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas.

Authors:  Isabela de Oliveira Amui; José Vicente Tagliarini; Emanuel C Castilho; Mariângela de Alencar Marques; Yoshio Kiy; José Eduardo Corrente; Gláucia M F S Mazeto
Journal:  Braz J Otorhinolaryngol       Date:  2017-10-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.